Month: August 2017

Laparoscopic Gastric Banding Prevents Type 2 Diabetes and Arterial Hypertension and Induces Their Remission in Morbid Obesity

Webmaster

Laparoscopic Gastric Banding Prevents Type 2 Diabetes and Arterial Hypertension and Induces Their Remission in Morbid Obesity Diabetes Care. 2005;28:2703-2709 ปี 2548 Authors: Antonio E. Pontiroli, MD1,2, Franco Folli, MD, PHD3, Michele Paganelli, MD4, Giancarlo Micheletto, MD5,Pierluigi Pizzocri, MD1,2, Paola Vedani, MD3, Francesca Luisi, PHD3, Lucia Perego, PHD3, Alberto Morabito, PHD1 andSanto Bressani Doldi, MD5 1 Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli Studi di Milano, Milan, Italy 2 Divisione di Medicina 2, Ospedale San Paolo, Milan, Italy 3 Divisione di Medicina, Ospedale San Raffaele, Milan, Italy 4 Divisione di Chirurgia, Ospedale San Raffaele, Milan, Italy 5 Dipartimento di Scienze Chirurgiche, Istituto Clinico Sant Ambrogio, Milan, Italy OBJECTIVE—Lifestyle modifications and pharmacological interventions can prevent type 2 diabetes in obese subjects with impaired glucose tolerance. The aim of this study was to compare laparoscopic adjustable gastric banding (LAGB) and conventional diet (No-LAGB) in the prevention (primary intervention study; 56 vs. […]

Read Post

Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure

Webmaster

Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure Diabetes Care 2005 28: 2345-2351 ปี 2548 Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure Authors: Dean T. Eurich, BSP, MSC1,2, Sumit R. Majumdar, MD, MPH1,3, Finlay A. McAlister, MD, MSC1,3, Ross T. Tsuyuki, BSC(PHARM), PHARMD, MSC1,2,4and Jeffrey A. Johnson, PHD1,2 Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada OBJECTIVE—Metformin is considered contraindicated in patients with heart failure because of concerns over lactic acidosis, despite increasing evidence of potential benefit. The aim of this study was to evaluate the association between metformin and clinical outcomes in patients with heart failure and type 2 diabetes.  RESEARCH DESIGN AND METHODS—Using the Saskatchewan Health databases, 12,272 new users of oral antidiabetic agents were identified between the years 1991 and 1996. Subjects with incident heart failure (n = 1,833) were identified through administrative records based on ICD-9 code 428 and grouped according to antidiabetic therapy: metformin monotherapy (n = […]

Read Post

Glycem

Webmaster

Glycem Diabetes Care 28 2436 2440 2005   Glycemic Status and Development of Kidney Disease The Framingham Heart Study Caroline S. Fox, MD, MPH1,2,3, Martin G. Larson, SCD1,4, Eric P. Leip, MS1,4, James B. Meigs, MD5, Peter W.F. Wilson, MD4 and Daniel Levy, MD1,3,4 1 National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, Massachusetts 2 Department of Endocrinology, Diabetes, and Hypertension, the Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 3 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 4 Boston University School of Medicine, Boston, Massachusetts 5 General Medicine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts Address correspondence and reprint requests to Caroline S. Fox, MD, MPH, Framingham Heart Study, 73 Mt. Wayte Ave. Suite 2, Framingham, MA 01702. E-mail: foxca@nhlbi.nih.gov   OBJECTIVE—Diabetes is a major risk factor for the development of kidney disease and is the […]

Read Post

Orlistat Is as Beneficial as Metformin in the Treatment of Polycystic Ovarian Syndrome

Webmaster

Orlistat Is as Beneficial as Metformin in the Treatment of Polycystic Ovarian Syndrome (ฉบับที่ 1 ปี 2548)           Department of Medicine, University of Hull, Michael White Centre for Diabetes and Endocrinology, Hull Royal Infirmary, Hull, U.K.; Department of Clinical Biochemistry and Immunology, Hull Royal Infirmary, Hull, U.K.; and Department of Medicine, York Hospital, York, U.K. Insulin resistance is increased in women with polycystic ovary syndrome (PCOS), and it may increase the risk of type 2 diabetes. In addition, hyperinsulinemia may contribute to androgen excess and could be a factor in the infertility associated with PCOS. This prospective, randomized, open-label study compared metformin therapy with orlistat in 21 women with PCOS. Orlistat reportedly produces significant, sustained weight loss and improves carbohydrate metabolism. After an 8-week period of dietary change, the women were randomized to receive either 500 mg metformin 3 times daily (n = 11) or 120 mg orlistat 3 times […]

Read Post